INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,377 | +3.5% | 5,057 | +25.8% | 0.00% | – |
| Q2 2023 | $254,408 | +32.0% | 4,020 | +13.0% | 0.00% | – |
| Q1 2023 | $192,786 | +16.1% | 3,559 | +14.3% | 0.00% | – |
| Q4 2022 | $166,000 | +7.8% | 3,114 | -5.9% | 0.00% | – |
| Q3 2022 | $154,000 | -84.1% | 3,308 | -80.5% | 0.00% | -100.0% |
| Q2 2022 | $966,000 | -35.8% | 16,932 | -31.1% | 0.00% | -33.3% |
| Q1 2022 | $1,504,000 | +1734.1% | 24,585 | +1467.9% | 0.00% | – |
| Q4 2021 | $82,000 | +127.8% | 1,568 | +63.3% | 0.00% | – |
| Q3 2021 | $36,000 | -20.0% | 960 | -13.2% | 0.00% | – |
| Q2 2021 | $45,000 | +87.5% | 1,106 | +55.6% | 0.00% | – |
| Q1 2021 | $24,000 | +4.3% | 711 | -3.4% | 0.00% | – |
| Q4 2020 | $23,000 | +4.5% | 736 | -13.7% | 0.00% | – |
| Q3 2020 | $22,000 | -63.3% | 853 | -63.9% | 0.00% | – |
| Q2 2020 | $60,000 | +81.8% | 2,363 | +9.9% | 0.00% | – |
| Q1 2020 | $33,000 | – | 2,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |